GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHF) » Definitions » Equity-to-Asset

Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Equity-to-Asset : 0.38 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sihuan Pharmaceutical Holdings Group's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $620.7 Mil. Sihuan Pharmaceutical Holdings Group's Total Assets for the quarter that ended in Dec. 2023 was $1,615.6 Mil. Therefore, Sihuan Pharmaceutical Holdings Group's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.38.

The historical rank and industry rank for Sihuan Pharmaceutical Holdings Group's Equity-to-Asset or its related term are showing as below:

SHPHF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.38   Med: 0.79   Max: 0.9
Current: 0.38

During the past 13 years, the highest Equity to Asset Ratio of Sihuan Pharmaceutical Holdings Group was 0.90. The lowest was 0.38. And the median was 0.79.

SHPHF's Equity-to-Asset is ranked worse than
73.3% of 1086 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs SHPHF: 0.38

Sihuan Pharmaceutical Holdings Group Equity-to-Asset Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Equity-to-Asset Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.76 0.71 0.57 0.39 0.38

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.50 0.39 0.37 0.38

Competitive Comparison of Sihuan Pharmaceutical Holdings Group's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sihuan Pharmaceutical Holdings Group's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Equity-to-Asset falls into.



Sihuan Pharmaceutical Holdings Group Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sihuan Pharmaceutical Holdings Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=620.729/1615.561
=0.38

Sihuan Pharmaceutical Holdings Group's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=620.729/1615.561
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sihuan Pharmaceutical Holdings Group  (OTCPK:SHPHF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Sihuan Pharmaceutical Holdings Group Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Business Description

Traded in Other Exchanges
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.